Editing Johnson & Johnson (section)

=== Illegal marketing of Risperdal ===
Juries in several US states have found J&J guilty of concealing the [[adverse effects]] of [[Janssen Pharmaceuticals]]' [[antipsychotic]] medication [[Risperdal]], produced by its unit, to promote it to doctors and patients as better than cheaper generics, and of falsely marketing it for treating patients with [[dementia]].<ref name="CNNMoney">{{Cite web | url = https://money.cnn.com/2013/11/04/news/companies/johnson-and-johnson-settlement/ | title = Johnson & Johnson to pay $2 billion for false marketing | date = November 4, 2013 | website = CNN Money | author = Gregory Wallace |access-date=November 6, 2013}}</ref> States that have awarded damages include [[Texas]] ($158{{nbs}}million), [[South Carolina]] ($327{{nbs}}million), [[Louisiana]] ($258{{nbs}}million), and most notably [[Arkansas]] ($1.2{{nbs}}billion).<ref>[https://www.nytimes.com/2012/04/12/business/drug-giant-is-fined-1-2-billion-in-arkansas.html?_r=0 J.&J. Fined $1.2{{nbs}}Billion in Drug Case] NY Times, By KATIE THOMAS Published: April 11, 2012</ref>

In 2010, the [[United States Department of Justice]] joined a [[whistleblowers]] suit accusing the company of illegally marketing Risperdal through [[Omnicare]], the largest company supplying pharmaceuticals to nursing homes.<ref name="Hilzenrath">{{Cite news|author=Hilzenrath, David S.|date=January 16, 2010|title=Justice suit accuses Johnson & Johnson of paying kickbacks|url=https://www.washingtonpost.com/wp-dyn/content/article/2010/01/15/AR2010011503903.html|newspaper=[[The Washington Post]] |access-date=January 17, 2010}}</ref><ref>{{Cite news|author=Singer, Natasha|date=January 15, 2010|title=Johnson & Johnson Accused of Drug Kickbacks |url=https://www.nytimes.com/2010/01/16/business/16drug.html|work=[[The New York Times]] |access-date=January 17, 2010}}</ref> The allegations include that J&J were warned by the FDA to not promote Risperdal as effective and safe for elderly patients, but they did so, and that they paid Omnicare to promote the drug to care home physicians.<ref>[https://www.bloomberg.com/news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html J&J Said to Agree to $2.2{{nbs}}Billion Drug Marketing Accord] Bloomberg News. By Margaret Cronin Fisk, Jef Feeley & David Voreacos{{snd}}June 11, 2012</ref> The settlement was finalized on November 4, 2013, with J&J agreeing to pay a penalty of around $2.2{{nbs}}billion, "including criminal fines and forfeiture totaling $485{{nbs}}million and civil settlements with the federal government and states totaling $1.72{{nbs}}billion".<ref name="DOH2013">{{Cite web|last1=Office of Public Affairs|first1=Department of Justice|title=Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations|url=https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations|publisher=United States Department of Justice|access-date=June 16, 2015|date=November 4, 2015}}</ref>

Johnson & Johnson has also been subject to congressional investigations related to payments given to [[psychiatrists]] to promote its products and [[ghost writer|ghost write]] articles, notably [[Joseph Biederman]] and his pediatric [[bipolar disorder]] research unit.<ref>[https://www.nytimes.com/2008/11/25/health/25psych.html Research Center Tied to Drug Company] By Gardiner Harris, The New York Times, 2008</ref>